Mohammed Elsayed

Dr. Mohammed Elsayed


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Acta Radiologica
Verified
Journal Article
Closed access
PDF file
MEMohammed Elsayed
Mohammed Elsayed
NKNadja Kadom
Nadja Kadom
CGComeron Ghobadi
Comeron Ghobadi
BSBenjamin Strauss
Benjamin Strauss
ODOmran Al Dandan
Omran Al Dandan
NSNabile M Safdar
Nabile M Safdar
The modern-day radiologist must be adept at image interpretation, and the one who most successfully leverages new technologies may provide the highest value to patients, clinicians, and trainees. Applications of virtual reality (VR) and augmented reality (AR) have the potential to revolutionize how imaging information is applied in clinical practice and how radiologists practice. This review provides an overview of VR and AR, highlights current applications, future developments, and limitations hindering adoption.

1 October 2020 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
MEMohammed Elsayed
Mohammed Elsayed
BCBernard Cheng
Bernard Cheng
MXMinzhi Xing
Minzhi Xing
ISIla Sethi
Ila Sethi
DBDavid Brandon
David Brandon
NKNima Kokabi
Nima Kokabi

10 January 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
MZMahdi Zirakchian Zadeh
Mahdi Zirakchian Zadeh
VSVlasios S Sotirchos
Vlasios S Sotirchos
AKAssen Kirov
Assen Kirov
DLDaniel Lafontaine
Daniel Lafontaine
MGMithat Gönen
Mithat Gönen
Constantinos T. SofocleousConstantinos T. Sofocleous
Constantinos T. Sofocleous

1 July 2023 in Radiology
Verified
Journal Article
Closed access
MEMohammed Elsayed
Mohammed Elsayed
SSStephen B. Solomon
Stephen B. Solomon
Interventional oncology is a subspecialty of interventional radiology focused on treating patients with cancer using minimally invasive, image-guided procedures. The role of interventional oncology has become so integral for supporting patients with cancer that many consider it the fourth pillar of oncology-a recent addition to the traditional pillars of medical oncology, surgery, and radiation oncology. As highlighted herein, the authors predict opportunities for growth in precision oncology, immunotherapy, advanced imaging, and novel interventions, facilitated by emergent technologies like artificial intelligence, gene editing, molecular imaging, and robotics. Beyond these technological breakthroughs, however, the defining characteristic of interventional oncology in 2043 will be a well-developed clinical and research infrastructure that enables greater integration of interventional oncology procedures into standard practice.

22 October 2014 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
SRSarah Ehab Riad
Sarah Ehab Riad
NENada El-Ekiaby
Nada El-Ekiaby
RMRadwa Yehia Mekky
Radwa Yehia Mekky
RARasha Ahmed
Rasha Ahmed
MDMohammad Ahmed Mohey EL Din
Mohammad Ahmed Mohey EL Din
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
Hepatits C virus (HCV) genotype 4 (GT4) shows low treatment response rates and discrepancies when compared to other genotypes. However, the reason underlying these discrepancies remains unclear due to the limited number of studies on GT4. microRNA‑155 (miR‑155) is a noteworthy example of a discrepancy in GT4, as it was found to be upregulated in genotypes 1, 2 and 3 HCV infection, but downregulated in GT4‑HCV‑infected peripheral blood mononuclear cells (PBMCs). The present study aimed to investigate the expression of miR‑155 in PBMCs, serum and liver tissues of GT4‑HCV‑infected patients. miR‑155 expression was assessed using reverse transcription‑quantitative polymerase chain reaction in GT4‑HCV‑infected PBMCs, serum and liver tissues, as well as GT2‑ and GT4‑infected Huh7 cells, and compared to the healthy controls. There was no difference in miR‑155 expression observed between naïve GT4‑HCV patients and healthy controls in the PBMCs and serum. In HCV‑infected liver tissues, however, a significant downregulation was observed. The unique miR‑155 expression pattern during GT4 infection was confirmed in the infected Huh7 cell lines when compared to GT2 infection. Clinical data showed a positive correlation between liver transaminases and serum miR‑155 expression. In addition, serum miR‑155 expression was significantly lower in naïve non‑responders (NRs) than naïve sustained virological responders (SVRs), and in post‑treatment NRs compared to post‑treatment SVRs. In conclusion, miR‑155 was not only proven to be a genotype‑specific microRNA that is not induced during GT4‑HCV infection, but also a good prognostic factor and predictor of response to treatment enabling a non‑invasive differentiation between NRs and SVRs during GT4‑HCV infection.

13 August 2014 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
DEDalia Sherif Elhelw
Dalia Sherif Elhelw
RMRadwa Yehia Mekky
Radwa Yehia Mekky
NENada El-Ekiaby
Nada El-Ekiaby
RARasha Ahmed
Rasha Ahmed
MEMohammad Ahmed Mohey Eldin
Mohammad Ahmed Mohey Eldin
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
MicroRNA (miRNA) expression in organs does not always represent their quantity in serum. A disparity in the expression of miR‑181a has been reported in the tissues and serum of hepatocellular carcinoma (HCC) patients. Since hepatitis C virus (HCV) is a major cause of HCC and miR‑181a has never been studied in HCV, the present study aimed to investigate the miR‑181a expression profile in genotype 4 (GT4)‑HCV patients to evaluate whether this pattern is also apparent in HCV. RNA was extracted from liver tissues, peripheral mononuclear cells (PBMCs) and serum samples from GT4‑HCV‑infected patients and healthy donors to evaluate the relative miR‑181a expression using quantitative reverse transcription‑polymerase chain reaction. miR‑181a was significantly higher in the serum of naïve patients compared to controls, and an inverse correlation with the viral load and liver enzymes was apparent. By contrast, no difference in miR‑181a expression was observed in the liver tissues and PBMCs of patients compared to controls. This expression observed in HCV is conflicting to that previously reported in HCC. The study also demonstrates a significant upregulation of miR‑181a post‑interferon/ribavirin treatment in the serum of sustained virological responders (SVRs) compared to non‑responders and treatment‑naïve SVRs. In conclusion, miR‑181a may be considered to be a possible prognostic marker in GT4‑HCV infection.